Texas Bank & Trust Co Decreases Holdings in Eli Lilly and Company $LLY

Texas Bank & Trust Co decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,595 shares of the company’s stock after selling 151 shares during the period. Eli Lilly and Company accounts for 1.6% of Texas Bank & Trust Co’s holdings, making the stock its 13th biggest position. Texas Bank & Trust Co’s holdings in Eli Lilly and Company were worth $3,795,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Corient IA LLC purchased a new position in shares of Eli Lilly and Company in the first quarter worth $570,000. LS Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock worth $1,933,000 after buying an additional 40 shares during the last quarter. Prism Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the first quarter worth $207,000. Hemington Wealth Management raised its holdings in shares of Eli Lilly and Company by 14.4% in the first quarter. Hemington Wealth Management now owns 985 shares of the company’s stock worth $813,000 after buying an additional 124 shares during the last quarter. Finally, Bfsg LLC increased its stake in shares of Eli Lilly and Company by 1.4% in the first quarter. Bfsg LLC now owns 2,959 shares of the company’s stock worth $2,444,000 after acquiring an additional 42 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In related news, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of research reports. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Guggenheim cut their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $950.17.

Eli Lilly and Company Stock Up 0.1%

LLY stock opened at $732.41 on Friday. The firm has a market cap of $693.20 billion, a PE ratio of 47.87, a P/E/G ratio of 1.02 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s fifty day moving average is $748.68 and its 200 day moving average is $786.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $969.65.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.